NASDAQ: ELABPmgc Holdings Inc Stock
$2.79+0.11 (+4.1%)
Updated Apr 22, 2025
ELAB Price
$2.79
Fair Value Price
$0.50
Market Cap
$1.97M
52 Week Low
$2.26
52 Week High
$1,064.00
P/E
-0.04x
P/B
0.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$5M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELAB Overview
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELAB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELAB
Ranked#314 of 463
Ranked#314 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.63 | A | |
| $7.89 | A | |
| $22.60 | A |
Be the first to know about important ELAB news, forecast changes, insider trades & much more!
ELAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELAB ($2.79) is overvalued by 457.25% relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELAB ($2.79) is not significantly undervalued (457.25%) relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELAB due diligence checks available for Premium users.
Valuation
ELAB fair value
Fair Value of ELAB stock based on Discounted Cash Flow (DCF)
Price
$2.79
Fair Value
$0.50
Overvalued by
457.25%
ELAB ($2.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELAB ($2.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
-208.37x
Market
28.14x
ELAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.3x
Industry
4.16x
ELAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELAB's financial health
Profit margin
Revenue
-$1.7M
Net Income
-$1.9M
Profit Margin
110.7%
ELAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.0M
Liabilities
$2.3M
Debt to equity
0.35
ELAB's short-term assets ($6.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELAB's short-term assets ($6.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.5B
Investing
$170.9M
Financing
-$6.8B
ELAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELAB vs Biotech Stocks
Pmgc Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.